SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Strong Long who wrote (1443)8/22/2015 1:10:05 PM
From: mokelumne river  Read Replies (1) of 2026
 
SL, you posted some "Pondering Qs" on ihub:

Pondering Q's:

Who were the interested parties (in Femprox) back in the day waiting on FDA ruling and approval of Flib, and was that the major sticking point?

We won't know the names of the interested parties but as I recall a main sticking point was that Apricus wanted to retain US rights but the prospective partners were leary of spending money for a Phase III approval for the UK (which would be used in part for FDA approval) and not benefitting from eventual US sales. That issue seems to have been resolved with Apricus now seeking a global partner.

Is exogenous testosterone the culprit when it comes to supplemental testosterone related health issues, and are elevated levels increased endogenously a safer alternative? Ref Fispemifine

The FDA is worried about elevated T levels resulting from T injections, particularly in men that do not suffer from primary hypogonadism. The drug formerly known as Andoxal and Fis will treat secondary hypogonadism. From the Apricus website: Fispemifene acts in secondary hypogonadism by inhibiting the negative feedback of testosterone production via an estrogen-blocking effect at the level of the pituitary, resulting in increased testosterone production in the testes, which in turn restores circulating testosterone levels to within, but not beyond, the normal range. (emphasis added)

Will Vitaros sell in a meaningful way, and when?

My guess is that sales will meaningfully increase when RTD is introduced in 2016/17. By then V should have considerable acceptance in the marketplace as a result of current partner efforts in Europe.

Money to operate the business?

That is the question that we all ponder and Eman reported on his discussions with Pascoe. The company has several options, some way better than others from a retail investor standpoint. A nice juicy deal for Femprox would help along with non-dilutive borrowing against future V royalties along with upfront money from more licensing deals for V. Perhaps licensing money for RayVa. We will see...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News